Effect of Rosiglitazone on Circulating Malondialdehyde (Mda) Level in Diabetes Based on a Systematic Review and Meta-Analysis of Eight Clinical Trials

Abstract

Patients with type 2 diabetes have high levels of malondialdehyde (MDA), and clinical data suggest a reducing effect of rosiglitazone (RSG) on the level of MDA in these patients. However, the results of available studies on the level of MDA in RSG-treated patients are not univocal. This meta-analysis aimed to assess the impact of RSG on the level of MDA. We performed a comprehensive search of PubMed, the Institute for Scientific Information Web of Science, Embase, Scopus, and Cochrane Library for related controlled trials until July 2020. Eligible studies were selected based on the inclusion criteria. Extracted data from each study were combined using a random-effects model. Sensitivity and subgroup analyses were conducted to explore potential heterogeneity. Eight trials with 456 subjects met the inclusion criteria. The results significantly showed the reducing effect of RSG on circulating MDA level (−0.47 μmol/mL; 95% CI −0.93 to −0.01; p=0.04; I2=82.1%; p heterogeneity=0.00) in individuals with T2D. No publication bias was observed with Begg’s rank correlation (p=0.71) and Egger’s linear regression (p=0.52) tests. Subgroup analyses showed that an intervention dose of 8 mg/day in serum samples was found to have a reducing effect on the level of MDA (−0.56 μmol/mL; 95% CI −0.98 to −0.14; p=0.008; I2=11.4%; p heterogeneity=0.32). Random-effects meta-regression did not show any significant association between the level of MDA and potential confounders including RSG dose, treatment duration, and sex. In conclusion, we found a significant reduction in MDA concentration in subjects with T2D who received a dose of 8 mg of RSG daily.

Effect and Mechanism of Schizandrin A in the Treatment of Liver Cancer Using Network Pharmacology, Molecular Docking, and Target Validation

“…32 Therefore, MDA content is an important parameter reflecting the potential antioxidant capacity of cells, which can reflect the rate and intensity of lipid peroxidation of cells and indirectly reflect the degree of tissue peroxidation damage. 33 The results of this study showed that SA could decrease the SOD and GSH-px levels of HepG2 cells, while increasing the MDA levels, with statistical significance ( P < .05). The results showed that SA could induce oxidative damage and apoptosis of HepG2 cells, indicating these as one of the important ways of its anti-liver cancer activity.…”

The Promising Role of Microbiome Therapy on Biomarkers of Inflammation and Oxidative Stress in Type 2 Diabetes: A Systematic and Narrative Review

“…Oxidative stress in diabetic patients leads to more severe diabetic complications. Lipid peroxidation results from the interaction of the lipid bilayer of a cell membrane with ROS and oxygen derived free radicals, producing malondialdehyde (MDA) ( 95 , 96 ). Elevated levels of MDA lead in subjects with T2D to many physiological effects, such as influencing the structural integrity of the cell membrane, inactivating surface enzymes and receptors on the membrane, and causing errors in cell regulation ( 97 ).…”